Rhinitis in Medical Technology
Navigation Links
Rhinitis in Medical Technology
... from moderate to severe persistent
allergic rhinitis to house dust mites, including 509 patients, over ... conduct of clinical trials in perennial allergic rhinitis is a major
challenge. The outcomes of the VO57.07 ... therapy".
About House Dust Mites Allergic rhinitis
In Europe, on average, almost 40% of ...
... in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, ... this data." ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 ... with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...
... allergy relief." Studies in allergic rhinitis patients demonstrated ... people in the United States. Seasonal allergic rhinitis (SAR), commonly referred to as "hay fever" or ... weeds, as well as mold. Perennial Allergic rhinitis (PAR) is sometimes referred to as "year round" or ...
... of MRX-4 in 16 patients suffering from allergic rhinitis (AR). MRX-4 was nasally administered as a ... challenge. ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 ... with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...
... dollar allergic rhinitis market". ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 million people in the United ... percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by ...
... corticosteroids in the treatment of very young children with allergic rhinitis has in the past raised concerns regarding potential effects on growth," ... growth charts were updated in 2000. About Allergic Rhinitis Allergic rhinitis is a swelling of the nasal passages, usually accompanied by sneezing, ...
... the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in ...
... in several products approved by the U.S. Food and Drug Administration (FDA), including products for the treatment of pediatric asthma, allergic rhinitis and Crohn's disease. Budesonide is a corticosteroid and has an established safety profile in those diseases. It works by decreasing inflammation in ...
... the signs and symptoms of allergic conjunctivitis. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku ...
... exposure chamber both before and after receiving the study treatment. During these "challenges" the volunteers will monitor and record their allergic rhinitis symptoms to allow investigators to assess the effect of the ToleroMune treatment. "We are delighted that this trial is making such rapid ...
... in the eight-week, doubleblind period were: nasopharyngitis (6.2 percent), headache (4.7 percent), fatigue (3.9 percent), vomiting (2.3 percent), rhinitis (2.3 percent) and creatine phosphokinase increase (2.3 percent). The most frequently reported adverse reactions during the additional 18-week ...
... suffering from mild to moderate seasonal allergic rhinitis due to grass pollen allergy. Upon entry into the ... (WHO, 2002). Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) ... a condition due to allergy that mimics a cold. rhinitis means "inflammation of the nasal ...
... patients suffering from mild to moderate allergic rhinitis due to house dust mite allergy and assessed in a ... from mild to moderate perennial allergic rhinitis due to house dust mite allergy. Upon entry into ... in clinical trials for the treatment of allergic rhinitis and atopic dermatitis. About allergic diseases ...
... placebo in 569 subjects who had a documented history of seasonal allergic rhinitis to mountain cedar pollen. Of the subjects randomized in the trial, 95% ... Drug Administration's (FDA) draft guidance document for seasonal allergic rhinitis and includes runny nose, nasal congestion, itchy nose and sneezing. ...
... and the patients’ allergies might have diminished during the treatment phase of the trial as the allergy season waned. Resolution of allergic rhinitis could improve asthma symptoms and other measures of asthma control in all patients independent of treatment. Our Phase 2b study was of a standard ...
... market size was approximately $500 million. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION(R). ...
... pain (14% vs. 8%) and nausea (13% vs. 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs. 50%), rhinitis (42% vs. 36%), diarrhea (35% vs. 50%), abdominal pain (32% vs. 44%) and flatulence (24% vs. 30%). Asacol is contraindicated in patients with ...
... to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of ...
... Roughly 60% of those continue to have AD also in adulthood2. Children with AD are at greater risk for developing other allergic diseases like rhinitis or asthma later in life. AD is characterized by a hypersensitivity reaction occurring in the skin that causes chronic inflammation and renders the ...
... in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, ... this data." ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 ... with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...
New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly
... . About Allergic Rhinitis Allergic rhinitis affects more than 50 million people in the ... seasonal and perennial. Seasonal allergic rhinitis (often referred to as "hay-fever") occurs ... grass and weed pollen. Perennial allergic rhinitis can occur throughout the year and is caused by ...... allergy relief." Studies in allergic rhinitis patients demonstrated ... people in the United States. Seasonal allergic rhinitis (SAR), commonly referred to as "hay fever" or ... weeds, as well as mold. Perennial Allergic rhinitis (PAR) is sometimes referred to as "year round" or ...
... of MRX-4 in 16 patients suffering from allergic rhinitis (AR). MRX-4 was nasally administered as a ... challenge. ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 ... with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...
New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
... ocular allergy symptoms of perennial allergic rhinitis (PAR) in patients 12 years of age and older, ... of symptoms of seasonal and perennial allergic rhinitis in adults and in children age two years and ... 12 years of age and older with perennial allergic rhinitis who were treated with Veramyst 110 mcg once daily ...Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
... scientific advisory board member. ABOUT ALLERGIC rhinitis Allergic rhinitis is a common condition that affects nearly 59 ... with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
... grass pollens, the allergen that causes rhinoconjunctivitis and allergic rhinitis in more than 50% of patients in Europe. With a safe and easy-to-use ... Nearly 15 to 20% of these patients suffer from moderate to severe allergic rhinitis and rhinoconjunctivitis, not controlled by their usual medical treatment. ...Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
... treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the ... market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is ...... dollar allergic rhinitis market". ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 million people in the United ... percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by ...
... corticosteroids in the treatment of very young children with allergic rhinitis has in the past raised concerns regarding potential effects on growth," ... growth charts were updated in 2000. About Allergic Rhinitis Allergic rhinitis is a swelling of the nasal passages, usually accompanied by sneezing, ...
Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting
... analysis of patients in the Midwest showed a correlation between higher rhinitis symptoms in the placebo group and measurable efficacy in the ... group overall did not demonstrate sufficient levels of ragweed allergic rhinitis and as a result, no meaningful clinical effect could be measured. ...... the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in ...
Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
... benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year. ToleroMune technology has additional potential ...Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
... benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with ...... in several products approved by the U.S. Food and Drug Administration (FDA), including products for the treatment of pediatric asthma, allergic rhinitis and Crohn's disease. Budesonide is a corticosteroid and has an established safety profile in those diseases. It works by decreasing inflammation in ...
... the signs and symptoms of allergic conjunctivitis. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku ...
... exposure chamber both before and after receiving the study treatment. During these "challenges" the volunteers will monitor and record their allergic rhinitis symptoms to allow investigators to assess the effect of the ToleroMune treatment. "We are delighted that this trial is making such rapid ...
... in the eight-week, doubleblind period were: nasopharyngitis (6.2 percent), headache (4.7 percent), fatigue (3.9 percent), vomiting (2.3 percent), rhinitis (2.3 percent) and creatine phosphokinase increase (2.3 percent). The most frequently reported adverse reactions during the additional 18-week ...
Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
... benefits, Circassia's anti-allergy products would have significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments, despite their limitations, is approximately $12 billion per year. The prevalence ...ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
... the signs and symptoms of allergic conjunctivitis. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku ...Study Says Allergy Shots Help Children, Reduce Health Care Costs
... reduces health care costs, even when the appropriate course of treatment is not completed. The study of 520 low-income Florida children with allergic rhinitis found that IT was associated with significant savings across all aspects of the health care system -- inpatient, outpatient and medication treatments ...... suffering from mild to moderate seasonal allergic rhinitis due to grass pollen allergy. Upon entry into the ... (WHO, 2002). Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) ... a condition due to allergy that mimics a cold. rhinitis means "inflammation of the nasal ...
... patients suffering from mild to moderate allergic rhinitis due to house dust mite allergy and assessed in a ... from mild to moderate perennial allergic rhinitis due to house dust mite allergy. Upon entry into ... in clinical trials for the treatment of allergic rhinitis and atopic dermatitis. About allergic diseases ...
... placebo in 569 subjects who had a documented history of seasonal allergic rhinitis to mountain cedar pollen. Of the subjects randomized in the trial, 95% ... Drug Administration's (FDA) draft guidance document for seasonal allergic rhinitis and includes runny nose, nasal congestion, itchy nose and sneezing. ...
... and the patients’ allergies might have diminished during the treatment phase of the trial as the allergy season waned. Resolution of allergic rhinitis could improve asthma symptoms and other measures of asthma control in all patients independent of treatment. Our Phase 2b study was of a standard ...
Pacgen Announces Positive Results from Phase I/II Trial of Novel Antifungal Drug
... with cellular immune deficiency states, such as HIV and AIDS. Patients with xerostomia and those treated with inhaled corticosteroids for asthma or rhinitis are also at risk. Oropharyngeal candidiasis infection can cause great discomfort, and if not treated, can spread from the primary site of ...... market size was approximately $500 million. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION(R). ...
... pain (14% vs. 8%) and nausea (13% vs. 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs. 50%), rhinitis (42% vs. 36%), diarrhea (35% vs. 50%), abdominal pain (32% vs. 44%) and flatulence (24% vs. 30%). Asacol is contraindicated in patients with ...
... to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of ...
Inspire Announces Presentations at Two European Scientific Conferences
... Poster and brief oral presentation on Tuesday, June 12, 2007 -- Treatment with Bilastine Improves Symptoms in Patients with Seasonal Allergic rhinitis (Phase 3 Study Comparing the Efficacy and Safety of Once Daily Bilastine with Desloratadine and Placebo for the Treatment of Seasonal ...... Roughly 60% of those continue to have AD also in adulthood2. Children with AD are at greater risk for developing other allergic diseases like rhinitis or asthma later in life. AD is characterized by a hypersensitivity reaction occurring in the skin that causes chronic inflammation and renders the ...
Other Contentsdrowningdrowningingestioningestioningestioningestioningestioningestionaddictionaddictionaddictionaddictionaddictionaddictiondrydrydrydrydrydrydrydrydryduodenalduodenaldyesdyesdyesdyesdyesdyesdysarthriadyspneadyspneadyspnea
Breaking Biology News(10 mins):New understanding of how to prevent destruction of a tumor suppressor 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 1Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 2Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 3Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 4Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 5Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 6Neurobiological Technologies Partner Celtic Pharma Announces Results of XERECEPT 28R 29 Phase 3 Clinical Program 4501 7Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 1Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 2Worth of Sigmoidoscopy Screening for Colon Cancer Still Uncertain 47450 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 1Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 2Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 3Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 4Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non Small Cell Lung Cancer 47446 5
Breaking Medicine News(10 mins):Health News:Docs Not Giving Clear Advice on Infant Sleep Positions 2Health News:Docs Not Giving Clear Advice on Infant Sleep Positions 3Health News:Health Reform is About You and Me, Not One or the Other 2Health News:Health Reform is About You and Me, Not One or the Other 3Health News:West Nile virus infection may persist in kidneys years after initial infection 2Health News:West Nile virus infection may persist in kidneys years after initial infection 3Health News:Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools 2Health News:Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools 3Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 2Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 3
Other TagsBUNBUNBUNBUNUltracentrifugesUltracentrifugeXpandXpandXpandXpand[0] Docs Not Giving Clear Advice on Infant Sleep Positions[0] Health Reform is About You and Me, Not One or the Other[0] West Nile virus infection may persist in kidneys years after initial infection[0] Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools[0] Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009
SGPTLiquidplusBUNABL5ABL555ABL77ABL700AVLMicroultracentrifugeUltracentrifugesTachometerUltracentrifugeXpandArx
Other Tagsnetworks 2networks 3networks 4networks 5inconsistent 2declare 2declare 3synthesize 2synthesize 3dogs 2wildlife 2wildlife 3wildlife 4wildlife 5linking 2linking 3linking 4does 2does 3does 4does 5does 6does 7does 8does 9does 10device 2device 3device 4device 5device 6device 7device 8device 9| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |